Área salud
Uso del anifrolumab en el lupus eritematoso sistémico, lupus eritematoso cutáneo y otras dermatosis autoinmunes
El anifrolumab es un inhibidor de la subunidad 1 del receptor del interferón tipo I (IFNAR1), recientemente aprobado para el tratamiento del lupus eritematoso sistémico (LES) moderado a grave. En dos ensayos clínicos demostró ser […]
Área salud
Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis
Introduction This article analyses the presence of gender bias in clinical trials of monoclonal antibodies used to treat multiple sclerosis. Material and methods We performed a systematic review of controlled clinical trials of 4 monoclonal […]
Área salud
Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses
Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous […]